Niagen Bioscience (NAGE) Gross Profit (2010 - 2026)

Niagen Bioscience (NAGE) has 17 years of Gross Profit data on file, last reported at $20.0 million in Q1 2026.

• On a quarterly basis, Gross Profit rose 3.34% year-over-year to $20.0 million in Q1 2026; TTM through Mar 2026 was $83.8 million, a 24.27% increase from a year earlier, with the FY2025 full-year figure at $83.2 million, up 35.08% from the prior year.
• Gross Profit for Q1 2026 stood at $20.0 million, down from $21.7 million in the prior quarter.
• Over the last five years, Gross Profit for NAGE reached as high as $21.9 million in Q3 2025 and fell as low as $10.0 million in Q2 2022.
• Historically, Gross Profit has averaged $15.2 million across 5 years, with a median of $13.5 million in 2023.
• Across the five-year window, Gross Profit slipped 7.1% in 2022 and jumped 47.71% in 2025, its largest moves.
• Year by year, Gross Profit stood at $12.0 million in 2022, then rose by 7.66% to $12.9 million in 2023, then soared by 40.66% to $18.2 million in 2024, then climbed by 19.27% to $21.7 million in 2025, then declined by 7.96% to $20.0 million in 2026.
• Per Business Quant data, the three most recent Gross Profit figures were $20.0 million in Q1 2026, $21.7 million in Q4 2025, and $21.9 million in Q3 2025.